查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601173

胜肽治療市場：按技術、藥物類別、給藥途徑、應用、最終用戶、製造類型分類 - 2025-2030 年全球預測

Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，胜肽治療市場估值為330.6億美元，預計2024年將達到357.6億美元，複合年成長率為8.35%，到2030年將達到579.7億美元。

肽治療學是生物技術和製藥領域的重要組成部分，由於其高度特異性、安全性和有效性，其重點關注胜肽作為藥物的使用。這種天然存在的生物分子由短鏈胺基酸組成，主要用於腫瘤學、代謝疾病和感染疾病等領域。對胜肽療法的需求源於其能夠精確靶向疾病途徑，並且與傳統小分子藥物相比副作用較少。應用於藥物傳遞系統、癌症免疫治療、抗菌劑等。典型的最終用戶包括醫院、專科診所、研究機構和製藥公司。市場成長是由生物活性胜肽研究的擴大、慢性病的流行以及胜肽合成和藥物傳遞技術的進步所推動的。胜肽工程和奈米技術的創新機會已經成熟，特別是在個人化醫療和再生療法方面。學術研究中心和製藥公司之間的合作可能會導致更多新應用的發現。然而，市場擴張面臨製造成本高、胜肽穩定性和交付複雜性以及阻礙研發過程的嚴格監管障礙等挑戰。此外，生物技術進步的不斷湧入加劇了競爭格局，需要靈活的研究策略。機會存在於需求快速成長的領域，例如基於胜肽的疫苗和診斷。化學合成的進步，例如固相胜肽合成的發展，提供了克服當前生產和成本限制的途徑。企業應注重多部門夥伴關係，以利用全面的專業知識和資源共用。市場的動態性質凸顯了突破性治療方法的潛力，旨在擴大治療性胜肽的穩定性和遞送機制的持續研究可能會開闢新的成長途徑。探索這些創新領域有望以重要方式重塑治療方法。

主要市場統計
基準年[2023] 330.6億美元
預測年份 [2024] 357.6億美元
預測年份 [2030] 579.7億美元
複合年成長率（%） 8.35%

市場動態：揭示快速發展的胜肽治療市場的關鍵市場洞察

供需的動態交互作用正在改變胜肽治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病流行和有效治療方案的需求
    • 擴大胜肽在美容皮膚病學的應用
  • 市場限制因素
    • 肽療法的不利召回
  • 市場機會
    • 持續進行研究和開發活動，在世界各地開發新的胜肽
    • 轉向個人化醫療和胜肽生物標記的鑑定
  • 市場挑戰
    • 胜肽治療藥物生產的複雜性與生物有效性問題

波特五力：駕馭胜肽治療市場的策略工具

波特的五力框架是了解胜肽治療市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胜肽治療市場的外部影響

外部宏觀環境因素在塑造胜肽治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解胜肽治療市場的競爭狀況

肽治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質胜肽治療市場供應商的績效評估

FPNV定位矩陣是評估胜肽治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和有效治療方法的需求
      • 多肽在美容皮膚科中的快速成長
    • 抑制因素
      • 回顧胜肽療法的不良反應
    • 機會
      • 持續進行研究和開發活動，在世界各地開發新的胜肽
      • 向個人化醫療的轉變和胜肽生物標記的鑑定
    • 任務
      • 胜肽治療藥物生產的複雜性與生物利用度問題
  • 市場區隔分析
    • 技術：在複雜胜肽的合成中增加固相方法的使用
    • 藥物類別：1 型和 2 型糖尿病患者對胰島素調節葡萄糖代謝的需求增加
    • 給藥途徑：在急診醫院護理環境中，靜脈注射因其即時和有效性而擴大被採用。
    • 應用：胜肽療法在心血管疾病中的廣泛應用，以模擬內源性胜肽參與血壓調節的作用
    • 最終使用者：擴大胜肽療法在醫院和診所的使用，以解決和管理病患病情
    • 製造類型：對專業製造能力和快速擴大生產能力的需求正在推動 CMO 招聘的增加。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章胜肽治療市場：依技術分類

  • 混合相
  • 液相
  • 固相

第7章依藥物類別分類的胜肽治療市場

  • 促腎上腺皮質激素
  • 抑鈣素
  • 胰島素
  • 亮丙瑞林
  • Octreotide
  • 加壓素

第8章胜肽治療市場：依給藥途徑

  • 靜脈注射
  • 鼻/肺給藥
  • 口服給藥
  • 經皮給藥

第9章胜肽治療市場：依應用分類

  • 心血管疾病
  • 胃腸道疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第10章胜肽治療市場：依最終用戶分類

  • 醫院/診所
  • 長期照護設施
  • 研究室

第11章按製造類型分類的胜肽治療市場

  • 契約製造組織
  • 公司內部

第12章美洲胜肽治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太多胜肽治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲胜肽治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 諾華和 PeptiDream 簽署了價值 1.8 億美元和 28 億美元的協議，合作開發先進的腫瘤治療方法。
    • 擴大法蘭克福 Kodenpharma 的 GMP 能力：改善早期胜肽 API 製造
    • 胜肽療法的革命：Orbis Medicines 徹底改變了口服藥物輸送
    • 總部位於哥本哈根的 Orbis Medicines 推出了一種胜肽療法，採用先進的大環技術，可提高口服生物有效性。
    • 擴大胜肽治療生產設施：藥明康德的策略成長
    • Glenmark Pharmaceuticals 宣佈在印度推出生物相似藥Liraglutide，徹底改變糖尿病治療
    • 推進Amido Technologies的創新製造平台與策略資本
    • 策略性收購提高了 Pharmathen 在胜肽治療市場的地位
    • Biosynth 透過策略收購 Pepceuticals 鞏固市場地位
    • PeptiDream 與 Genentech 結成策略聯盟，推進胜肽放射性同位素治療
    • 默克和 IRBM 在胜肽治療領域取得進展：生物製藥擴張和創新合作
    • 富士通宣布推出開創性生物製藥設計加速器，專注於癌症和中樞神經系統再生的進展
    • 引入Sincrest CRDMO服務，為從概念到製造的開發提供全面支持

公司名單

  • AbbVie Inc.
  • AmbioPharm, Inc.
  • Amgen Inc.
  • Amide Technologies, Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Biosynth Ltd.
  • Bristol Myers Squibb Company
  • Cidara Therapeutics, Inc.
  • Corden Pharma International GmbH
  • Cybrexa, Inc.
  • Eccogene
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Ipsen Group
  • IRBM SpA
  • Ironwood Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Peptidream Co., Ltd.
  • Perpetual Medicines Corporation
  • Pfizer Inc.
  • Piramal Pharma Limited
  • PolyPeptide Group AG
  • RELIEF THERAPEUTICS Holding SA
  • Sanofi SA
  • Sanyou Biopharmaceuticals Co., Ltd.
  • Shanghai Full-Life Technologies Co, Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • WuXi AppTec Co., Ltd.
  • Zealand Pharma A/S
Product Code: MRR-030EE4851583

The Peptide Therapeutics Market was valued at USD 33.06 billion in 2023, expected to reach USD 35.76 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 57.97 billion by 2030.

Peptide therapeutics, a vital segment within the biotechnology and pharmaceutical sectors, focus on the use of peptides as drugs due to their high specificity, safety, and efficacy. These naturally occurring biological molecules, consisting of short chains of amino acids, cater primarily to areas such as oncology, metabolic disorders, and infectious diseases. The necessity for peptide therapeutics arises from their ability to precisely target disease pathways with fewer side effects compared to traditional small molecule drugs. They find application in drug delivery systems, cancer immunotherapy, and as antimicrobial agents. Key end-users include hospitals, specialized clinics, research institutes, and pharmaceutical companies. Market growth is driven by expanding research into biologically active peptides, escalating prevalence of chronic diseases, and advancements in peptide synthesis and drug delivery technologies. Opportunities are ripe, especially in personalized medicine and regenerative therapies, enhanced by innovations in peptide engineering and nanotechnology. Collaboration between academic research centers and pharmaceutical companies can further uncover novel applications. However, market expansion faces challenges such as high production costs, complexities in peptide stability and delivery, and stringent regulatory hurdles that can impede R&D processes. Additionally, the competitive landscape is intensified by the constant influx of biotechnological advancements, necessitating agile research strategies. Opportunities exist in areas like peptide-based vaccines and diagnostics where demand is burgeoning. Advances in chemical synthesis, such as the development of solid-phase peptide synthesis, present pathways for overcoming current production and cost limitations. Firms should focus on multisector partnerships to leverage comprehensive expertise and resource sharing. The market's dynamic nature underscores the potential for groundbreaking treatments, with ongoing research directed at expanding therapeutic peptides' stability and delivery mechanisms likely to usher in new growth avenues. Exploring these areas for innovation promises to reshape therapeutic approaches in significant ways.

KEY MARKET STATISTICS
Base Year [2023] USD 33.06 billion
Estimated Year [2024] USD 35.76 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 8.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Therapeutics Market

The Peptide Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for effective therapeutic options
    • Exponential use of peptides in aesthetic dermatology
  • Market Restraints
    • Adverse recalls of peptide therapeutics
  • Market Opportunities
    • Ongoing R&D activities for new peptide development worldwide
    • Shift toward personalized medicine and identification of peptide biomarkers
  • Market Challenges
    • Production complexity and bioavailability issues of peptide therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Therapeutics Market

A detailed market share analysis in the Peptide Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Hybrid Phase, Liquid Phase, and Solid Phase.
  • Based on Drug Class, market is studied across Adrenocorticotropic Hormone, Calcitonin, Insulin, Leuprorelin, Octreotide, and Vasopressin.
  • Based on Route of Administration, market is studied across Intravenous Administration, Nasal & Pulmonary Administration, Oral Administration, and Transdermal Administration.
  • Based on Application, market is studied across Cardiovascular Disorders, Gastrointestinal Disorders, Infectious Disorders, Neurological Disorders, and Oncology.
  • Based on End User, market is studied across Hospitals & Clinics, Long-term Care Facilities, and Research Laboratories.
  • Based on Manufacturing Type, market is studied across Contract Manufacturing Organization and In-house.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
      • 5.1.1.2. Exponential use of peptides in aesthetic dermatology
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of peptide therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
      • 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
    • 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
    • 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
    • 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
    • 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
    • 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peptide Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Hybrid Phase
  • 6.3. Liquid Phase
  • 6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Adrenocorticotropic Hormone
  • 7.3. Calcitonin
  • 7.4. Insulin
  • 7.5. Leuprorelin
  • 7.6. Octreotide
  • 7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous Administration
  • 8.3. Nasal & Pulmonary Administration
  • 8.4. Oral Administration
  • 8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Infectious Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology

10. Peptide Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Clinics
  • 10.3. Long-term Care Facilities
  • 10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

  • 11.1. Introduction
  • 11.2. Contract Manufacturing Organization
  • 11.3. In-house

12. Americas Peptide Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Novartis and PeptiDream collaborated to develop advanced oncology therapies with a USD 180 million deal a USD 2.8 billion deal
    • 15.3.2. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
    • 15.3.3. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
    • 15.3.4. Copenhagen's Orbis Medicines launched peptide therapeutics with advanced macrocyclic technology for enhanced oral bioavailability
    • 15.3.5. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
    • 15.3.6. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
    • 15.3.7. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
    • 15.3.8. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
    • 15.3.9. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
    • 15.3.10. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
    • 15.3.11. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
    • 15.3.12. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
    • 15.3.13. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AmbioPharm, Inc.
  • 3. Amgen Inc.
  • 4. Amide Technologies, Inc.
  • 5. AstraZeneca PLC
  • 6. Bachem Holding AG
  • 7. Biosynth Ltd.
  • 8. Bristol Myers Squibb Company
  • 9. Cidara Therapeutics, Inc.
  • 10. Corden Pharma International GmbH
  • 11. Cybrexa, Inc.
  • 12. Eccogene
  • 13. Eli Lilly and Company
  • 14. Exelixis, Inc.
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Ipsen Group
  • 18. IRBM S.p.A.
  • 19. Ironwood Pharmaceuticals, Inc.
  • 20. Merck KGaA
  • 21. Novartis AG
  • 22. Novo Nordisk A/S
  • 23. Otsuka Pharmaceutical Co., Ltd.
  • 24. Peptidream Co., Ltd.
  • 25. Perpetual Medicines Corporation
  • 26. Pfizer Inc.
  • 27. Piramal Pharma Limited
  • 28. PolyPeptide Group AG
  • 29. RELIEF THERAPEUTICS Holding SA
  • 30. Sanofi S.A.
  • 31. Sanyou Biopharmaceuticals Co., Ltd.
  • 32. Shanghai Full-Life Technologies Co, Ltd.
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Teva Pharmaceutical Industries Limited
  • 35. WuXi AppTec Co., Ltd.
  • 36. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023